Eric Soler

Montpellier, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-Skewed Hematopoiesis in Sickle Cell Anemia.

IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-Skewed Hematopoiesis in Sickle Cell Anemia.

Journal: American journal of hematology
Published: February 17, 2026

ZEB1 drives terminal erythroid maturation by controlling the GATA2-KLF1 regulatory switch.

ZEB1 drives terminal erythroid maturation by controlling the GATA2-KLF1 regulatory switch.

Journal: Nucleic acids research
Published: December 17, 2025

IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia.

IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia.

Journal: Research square
Published: November 24, 2025

VEXAS anemia is a mosaic erythroblastopenia.

VEXAS anemia is a mosaic erythroblastopenia.

Journal: Blood
Published: March 10, 2025

VEXAS anemia is a mosaic erythroblastopenia.

VEXAS anemia is a mosaic erythroblastopenia.

Journal: Blood
Published: March 10, 2025

In vivo deletion of a GWAS-identified Myb distal enhancer acts on Myb expression, globin switching, and clinical erythroid parameters in β-thalassemia.

In vivo deletion of a GWAS-identified Myb distal enhancer acts on Myb expression, globin switching, and clinical erythroid parameters in β-thalassemia.

Journal: Scientific reports
Published: January 13, 2025

The methyl-CpG-binding protein 2 inhibits cGAS-associated signaling.

The methyl-CpG-binding protein 2 inhibits cGAS-associated signaling.

Journal: Nature communications
Published: December 26, 2024

MMS22L is a novel key actor of normal and pathological erythropoiesis.

MMS22L is a novel key actor of normal and pathological erythropoiesis.

Journal: HemaSphere
Published: November 04, 2024

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.

Journal: HemaSphere
Published: March 01, 2024

Protocol for efficient CRISPR-Cas9-mediated fluorescent tag knockin in hard-to-transfect erythroid cell lines.

Protocol for efficient CRISPR-Cas9-mediated fluorescent tag knockin in hard-to-transfect erythroid cell lines.

Journal: STAR protocols
Published: January 16, 2024

Efficient genome editing in erythroid cells unveils novel MYB target genes and regulatory functions.

Efficient genome editing in erythroid cells unveils novel MYB target genes and regulatory functions.

Journal: iScience
Published: March 27, 2023

High-throughput methods for the analysis of transcription factors and chromatin modifications: Low input, single cell and spatial genomic technologies.

High-throughput methods for the analysis of transcription factors and chromatin modifications: Low input, single cell and spatial genomic technologies.

Journal: Blood cells, molecules & diseases
Published: January 27, 2023
Showing 1-12 of 44

Last Updated: 09/26/2026